Compare Stocks: ACAD, BBIO, ASND, and ELAN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.87 -2.6%	$23.74	$19.69 ▼ $28.35	$4.55B	0.8	1.34 million shs	1.53 million shs
ASND Ascendis Pharma A/S	$243.91 -2.9%	$244.95	$167.27 ▼ $282.15	$15.66B	0.37	488,616 shs	508,875 shs
BBIO BridgeBio Pharma	$80.09 -2.5%	$74.22	$42.09 ▼ $93.42	$16.06B	0.95	3.26 million shs	2.13 million shs
ELAN Elanco Animal Health	$26.42 -0.1%	$24.55	$13.39 ▼ $27.72	$13.22B	1.68	4.30 million shs	5.19 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-2.56%	+4.15%	+2.66%	+17.86%	+9.94%
ASND Ascendis Pharma A/S	-2.85%	-3.92%	-8.92%	+10.40%	+46.25%
BBIO BridgeBio Pharma	-2.50%	-4.68%	+7.47%	+16.82%	+75.56%
ELAN Elanco Animal Health	-0.21%	+6.12%	+9.76%	+17.22%	+87.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.87 -2.6%	$23.74	$19.69 ▼ $28.35	$4.55B	0.8	1.34 million shs	1.53 million shs
ASND Ascendis Pharma A/S	$243.91 -2.9%	$244.95	$167.27 ▼ $282.15	$15.66B	0.37	488,616 shs	508,875 shs
BBIO BridgeBio Pharma	$80.09 -2.5%	$74.22	$42.09 ▼ $93.42	$16.06B	0.95	3.26 million shs	2.13 million shs
ELAN Elanco Animal Health	$26.42 -0.1%	$24.55	$13.39 ▼ $27.72	$13.22B	1.68	4.30 million shs	5.19 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-2.56%	+4.15%	+2.66%	+17.86%	+9.94%
ASND Ascendis Pharma A/S	-2.85%	-3.92%	-8.92%	+10.40%	+46.25%
BBIO BridgeBio Pharma	-2.50%	-4.68%	+7.47%	+16.82%	+75.56%
ELAN Elanco Animal Health	-0.21%	+6.12%	+9.76%	+17.22%	+87.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.67	Moderate Buy	$32.31	24.88% Upside
ASND Ascendis Pharma A/S	3.05	Buy	$296.72	21.65% Upside
BBIO BridgeBio Pharma	2.83	Moderate Buy	$95.21	18.88% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$28.73	8.72% Upside

Current Analyst Ratings Breakdown

Latest ACAD, BBIO, ASND, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.50
7/23/2026	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$256.00 ➝ $275.00
7/22/2026	ELAN Elanco Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$23.00 ➝ $26.00
7/21/2026	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$34.00 ➝ $36.00
7/21/2026	ACAD ACADIA Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$24.00 ➝ $25.00
7/16/2026	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$82.00 ➝ $93.00
7/15/2026	ASND Ascendis Pharma A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C)
7/13/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $120.00
7/7/2026	ASND Ascendis Pharma A/S	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $280.00
7/7/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$29.00 ➝ $36.00

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.13	$0.86 per share	29.93	$7.25 per share	3.57
ASND Ascendis Pharma A/S	$814.57M	18.68	N/A	N/A	($2.97) per share	-82.12
BBIO BridgeBio Pharma	$502.08M	31.18	N/A	N/A	($10.77) per share	-7.44
ELAN Elanco Animal Health	$4.72B	2.80	$2.32 per share	11.40	$13.18 per share	2.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.20	11.76	26.95	18.41	34.30%	9.61%	7.07%	8/4/2026 (Confirmed)
ASND Ascendis Pharma A/S	-$258M	$8.67	28.13	21.15	N/A	57.87%	N/A	-8.37%	8/6/2026 (Estimated)
BBIO BridgeBio Pharma	-$724.93M	-$3.74	N/A	1,334.83	N/A	-124.42%	N/A	-65.81%	8/4/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.50	N/A	21.31	1.73	-4.95%	7.42%	3.66%	8/5/2026 (Estimated)

Latest ACAD, BBIO, ASND, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	N/A	N/A	N/A	$376.75 million	N/A
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	N/A	N/A	N/A	$1.31 billion	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0581	N/A	N/A	N/A	$295.51 million	N/A
8/4/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5816	N/A	N/A	N/A	$221.15 million	N/A
5/7/2026	Q1 2026	ASND Ascendis Pharma A/S	$0.21	$0.32	+$0.11	$11.29	$362.47 million	$285.45 million
5/7/2026	Q1 2026	BBIO BridgeBio Pharma	-$0.70	-$0.84	-$0.14	-$0.84	$178.07 million	$194.52 million
5/6/2026	Q1 2026	ACAD ACADIA Pharmaceuticals	$0.04	$0.02	-$0.02	$0.02	$280.25 million	$268.10 million
5/6/2026	Q1 2026	ELAN Elanco Animal Health	$0.34	$0.40	+$0.06	$0.11	$1.28 billion	$1.37 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.59	3.48
ASND Ascendis Pharma A/S	0.79	1.00	0.72
BBIO BridgeBio Pharma	N/A	1.52	1.48
ELAN Elanco Animal Health	0.60	2.16	1.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ASND Ascendis Pharma A/S	N/A
BBIO BridgeBio Pharma	99.85%
ELAN Elanco Animal Health	97.48%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
ASND Ascendis Pharma A/S	40.00%
BBIO BridgeBio Pharma	14.23%
ELAN Elanco Animal Health	1.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	171.24 million	126.37 million	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
BBIO BridgeBio Pharma	400	195.49 million	167.67 million	Optionable
ELAN Elanco Animal Health	9,400	499.45 million	493.76 million	Optionable

ACAD, BBIO, ASND, and ELAN Headlines

Recent News About These Companies

Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

July 31 at 7:32 AM | prnewswire.com

Elanco Animal Health Incorporated $ELAN Shares Sold by Quantinno Capital Management LP

July 31 at 5:21 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Acquires 641,448 Shares of Elanco Animal Health Incorporated $ELAN

July 31 at 3:11 AM | marketbeat.com

Expert warns pet owners of risky parasites targeting animals

July 29 at 2:35 PM | fox21news.comF

Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says

July 29 at 2:35 PM | finance.yahoo.com

Elanco Animal Health CFO Robert VanHimbergen Purchases Deferred Stock Units in July 2026 SEC Filing

July 29 at 2:35 PM | kalkinemedia.comK

Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: Should You Buy?

July 29 at 11:06 AM | zacks.com

Elanco Animal Health (ELAN) Expected to Release Earnings on Wednesday

July 29 at 10:55 AM | marketbeat.com

Elanco Animal Health Incorporated $ELAN Shares Sold by The Manufacturers Life Insurance Company

July 29 at 6:47 AM | marketbeat.com

Elanco Animal Health Incorporated $ELAN is Redwood Grove Capital LLC's Largest Position

July 29 at 5:51 AM | marketbeat.com

Castleark Management LLC Raises Stock Position in Elanco Animal Health Incorporated $ELAN

July 27, 2026 | marketbeat.com

Elanco (ELAN) Stock Looks Below Fair Value While A 108% Return Tests Upside

July 26, 2026 | finance.yahoo.com

Did New Tick-Data Edge for Credelio Quattro Just Shift Elanco Animal Health's (ELAN) Investment Narrative?

July 26, 2026 | finance.yahoo.com

Elanco Animal Health Incorporated $ELAN Shares Purchased by Sei Investments Co.

July 24, 2026 | marketbeat.com

Morgan Stanley Increases Elanco Animal Health (NYSE:ELAN) Price Target to $26.00

July 24, 2026 | americanbankingnews.com

Morgan Stanley Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

July 22, 2026 | marketbeat.com

Are You Looking for a Top Momentum Pick? Why Elanco Animal Health Incorporated (ELAN) is a Great Choice

July 22, 2026 | zacks.com

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

July 22, 2026 | prnewswire.com

Elanco Animal Health Incorporated $ELAN Shares Sold by Bank of New York Mellon Corp

July 22, 2026 | marketbeat.com

Dimensional Fund Advisors LP Has $586.92 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

July 21, 2026 | marketbeat.com

Jennison Associates LLC Purchases 494,216 Shares of Elanco Animal Health Incorporated $ELAN

July 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACAD, BBIO, ASND, and ELAN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.87 -0.68 (-2.56%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$25.72 -0.16 (-0.60%)

As of 07/31/2026 07:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S NASDAQ:ASND

$243.91 -7.16 (-2.85%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$243.78 -0.13 (-0.06%)

As of 07/31/2026 07:34 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma NASDAQ:BBIO

$80.09 -2.05 (-2.50%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$80.27 +0.18 (+0.22%)

As of 07/31/2026 07:34 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health NYSE:ELAN

$26.42 -0.04 (-0.14%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$25.49 -0.93 (-3.53%)

As of 07/31/2026 07:37 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACAD, BBIO, ASND, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACAD, BBIO, ASND, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACAD, BBIO, ASND, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACAD, BBIO, ASND, and ELAN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Elanco Animal Health NYSE:ELAN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACAD, BBIO, ASND, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACAD, BBIO, ASND, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACAD, BBIO, ASND, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACAD, BBIO, ASND, and ELAN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Elanco Animal Health NYSE:ELAN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools